- melanoma," Cancer Research, vol. 64, no. 18, pp. 6372-6376, 2004.
- [138] D. Tormo, A. Ferrer, E. Gaffal, et al., "Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation," American Journal of Pathology, vol. 169, no. 2, pp. 665-672, 2006.
- [139] C. Berking and M. Herlyn, "Human skin reconstruct models: a new application for studies of melanocyte and melanoma biology," *Histology and Histopathology*, vol. 16, no. 2, pp. 669– 674, 2001.
- [140] S. Mohapatra, D. Coppola, A. I. Riker, and W. J. Pledger, "Roscovitine inhibits differentiation and invasion in a three-dimensional skin reconstruction model of metastatic melanoma," Molecular Cancer Research, vol. 5, no. 2, pp. 145– 151, 2007.
- [141] L.-K. Su, K. W. Kinzler, B. Vogelstein, et al., "Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene," Science, vol. 256, no. 5057, pp. 668-670, 1992.
- [142] W. Edelmann, K. Yang, M. Kuraguchi, et al., "Tumorigenesis in Mlh1 and Mlh1/Apc1638N mutant mice," Cancer Research, vol. 59, no. 6, pp. 1301–1307, 1999.
- [143] T. Tanaka, H. Kohno, R. Suzuki, et al., "Dextran sodium sulfate strongly promotes colorectal carcinogenesis in ApcMin/+ mice: inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms," International Journal of Cancer, vol. 118, no. 1, pp. 25–34, 2006.
- [144] H. Tsuda, M. Asamoto, T. Ochiya, et al., "High susceptibility of transgenic rats carrying the human c-Ha-ras protooncogene to chemically-induced mammary carcinogenesis," Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 477, no. 1-2, pp. 173-182, 2001.
- [145] S. Miyamoto, Y. Yasui, M. Kim, et al., "A novel rasH2 mouse carcinogenesis model that is highly susceptible to 4-NQOinduced tongue and esophageal carcinogenesis is useful for preclinical chemoprevention studies," Carcinogenesis, vol. 29, no. 2, pp. 418–426, 2008.
- [146] R. Suzuki, H. Kohno, M. Suzui, et al., "An animal model for the rapid induction of tongue neoplasms in human c-Ha-ras proto-oncogene transgenic rats by 4-nitroquinoline 1-oxide: its potential use for preclinical chemoprevention studies," Carcinogenesis, vol. 27, no. 3, pp. 619-630, 2006.
- [147] S. Ueda, K. Fukamachi, Y. Matsuoka, et al., "Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras oncogene in rat pancreas," Carcinogenesis, vol. 27, no. 12, pp. 2497-2510, 2006.
- [148] K. Kiguchi, S. Carbajal, K. Chan, et al., "Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma," Cancer Research, vol. 61, no. 19, pp. 6971-6976, 2001.
- [149] B. S. Reddy, "Strategies for colon cancer prevention: combination of chemopreventive agents," Sub-Cellular Biochemistry, vol. 42, pp. 213–225, 2007.
- [150] T. Tanaka, H. Makita, K. Kawabata, et al., "Chemoprevention of azoxymethane-induced rat colon carcinogenesis by the naturally occurring flavonoids, diosmin and hesperidin," Carcinogenesis, vol. 18, no. 5, pp. 957-965, 1997.
- [151] T. A. Ratko, C. J. Detrisac, N. M. Dinger, C. F. Thomas, G. J. Kelloff, and R. C. Moon, "Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats," Cancer Research, vol. 49, no. 16, pp. 4472-4476, 1989.

- [152] C. V. Rao, K. Tokumo, J. Rigotty, E. Zang, G. Kelloff, and B. S. Reddy, "Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, α-difluoromethylornithine, 16α-fluoro-5-androsten-17-one, and ellagic acid individually and in combination," Cancer Research, vol. 51, no. 17, pp. 4528–4534, 1991.
- [153] B. S. Reddy, J. Nayini, K. Tokumo, J. Rigotty, E. Zang, and G. Kelloff, "Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-α-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet," Cancer Research, vol. 50, no. 9, pp. 2562–2568, 1990.
- [154] G. Shen, T. O. Khor, R. Hu, et al., "Chemoprevention of familial adenomatous polyposis by natural dietary compounds sulforaphane and dibenzoylmethane alone and in combination in ApcMin/+ mouse," Cancer Research, vol. 67, no. 20, pp. 9937-9944, 2007.
- [155] B. A. Narayanan, B. S. Reddy, M. C. Bosland, et al., "Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence," Clinical Cancer Research, vol. 13, no. 19, pp. 5965-5973, 2007.
- [156] T.-T. Chang and T.-C. Chou, "Rational approach to the clinical protocol design for drug combinations: a review," Acta Paediatrica Taiwanica, vol. 41, no. 6, pp. 294–302, 2000.
- [157] T.-C. Chou, "Preclinical versus clinical drug combination studies," *Leukemia and Lymphoma*, vol. 49, no. 11, pp. 2059– 2080, 2008.
- [158] T.-C. Chou and P. Talalay, "Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors," Advances in Enzyme Regulation, vol. 22, pp. 27-55, 1984.
- [159] T. C. Chou and P. Talalay, "A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems," The Journal of Biological Chemistry, vol. 252, no. 18, pp. 6438-6442, 1977.
- [160] T. Rabi and A. Bishayee, "Terpenoids and breast cancer chemoprevention," Breast Cancer Research and Treatment. In press.
- [161] J. Sudbø, M. Bryne, L. Mao, et al., "Molecular based treatment of oral cancer," Oral Oncology, vol. 39, no. 8, pp. 749-758, 2003.
- [162] J. R. Marshall, "Prevention of colorectal cancer: diet, chemoprevention, and lifestyle," Gastroenterology Clinics of North America, vol. 37, no. 1, pp. 73–82, 2008.
- [163] P. Greenwald, "From carcinogenesis to clinical interventions for cancer prevention," *Twicology*, vol. 166, no. 1-2, pp. 37– 45, 2001.
- [164] S. De Flora, A. Izzotti, F. D'Agostini, et al., "Induction and modulation of lung tumors: genomic and transcriptional alterations in cigarette smoke-exposed mice," Experimental Lung Research, vol. 31, no. 1, pp. 19-35, 2005.
- [165] A. S. Tsao, E. S. Kim, and W. K. Hong, "Chemoprevention of cancer," CA: A Cancer Journal for Clinicians, vol. 54, no. 3, pp. 150–180, 2004.
- [166] W. B. Armstrong, T. H. Taylor, and F. L. Meyskens, "Can a marker be a surrogate for development of cancer, and would we know it if it exists?" Recent Results in Cancer Research, vol. 166, pp. 99-112, 2005.
- [167] S. Bettuzzi, M. Brausi, F. Rizzi, G. Castagnetti, G. Peracchia, and A. Corti, "Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers

- with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study," Cancer Research, vol. 66, no. 2, pp. 1234-1240, 2006.
- [168] R. Lieberman, "Evolving strategies for prostate cancer chemoprevention trials," World Journal of Urology, vol. 21, no. 1, pp. 3-8, 2003.
- [169] W. M. van Weerden and F. H. Schröder, "The use of PSA as biomarker in nutritional intervention studies of prostate cancer," *Chemico-Biological Interactions*, vol. 171, no. 2, pp. 204-211, 2008.
- [170] K. J. Auborn, S. Fan, E. M. Rosen, et al., "Indole-3-carbinol is a negative regulator of estrogen," *The Journal of Nutrition*, vol. 133, supplement 7, pp. 2470S-2475S, 2003.
- [171] D. Heber, "Multitargeted therapy of cancer by ellagitannins," Cancer Letters, vol. 269, no. 2, pp. 262–268, 2008.
- [172] J. D. Clarke, R. H. Dashwood, and E. Ho, "Multi-targeted prevention of cancer by sulforaphane," Cancer Letters, vol. 269, no. 2, pp. 291-304, 2008.
- [173] R. B. van Breemen and N. Pajkovic, "Multitargeted therapy of cancer by lycopene," Cancer Letters, vol. 269, no. 2, pp. 339– 351, 2008.
- [174] A. A. Powolny and S. V. Singh, "Multitargeted prevention and therapy of cancer by diallyl trisulfide and related Allium vegetable-derived organosulfur compounds," Cancer Letters, vol. 269, no. 2, pp. 305-314, 2008.
- [175] I. M. Berquin, I. J. Edwards, and Y. Q. Chen, "Multi-targeted therapy of cancer by omega-3 fatty acids," *Cancer Letters*, vol. 269, no. 2, pp. 363-377, 2008.
- [176] V. Nandakumar, T. Singh, and S. K. Katiyar, "Multi-targeted prevention and therapy of cancer by proanthocyanidins," *Cancer Letters*, vol. 269, no. 2, pp. 378-387, 2008.
- [177] N. Khan and H. Mukhtar, "Multitargeted therapy of cancer by green tea polyphenols," Cancer Letters, vol. 269, no. 2, pp. 269–280, 2008.
- [178] S. Banerjee, Y. Li, Z. Wang, and F. H. Sarkar, "Multi-targeted therapy of cancer by genistein," *Cancer Letters*, vol. 269, no. 2, pp. 226-242, 2008.
- [179] K. Ramasamy and R. Agarwal, "Multitargeted therapy of cancer by silymarin," Cancer Letters, vol. 269, no. 2, pp. 352– 362, 2008.
- [180] A. B. Kunnumakkara, P. Anand, and B. B. Aggarwal, "Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins," Cancer Letters, vol. 269, no. 2, pp. 199-225, 2008.
- [181] H. Hatcher, R. Planalp, J. Cho, F. M. Torti, and S. V. Torti, "Curcumin: from ancient medicine to current clinical trials," Cellular and Molecular Life Sciences, vol. 65, no. 11, pp. 1631– 1652, 2008.